Background {#Sec1}
==========

The prevalence of infection is high among patients admitted to ICUs and is one of the main causes of ICU mortality \[[@CR1], [@CR2]\]. In 1992, a one-day European point-prevalence study on infections in intensive care (EPIC), performed in 1417 ICUs in 17 Western European countries \[[@CR3]\], showed that approximately 45% of all patients present on the ICU on the study day were infected. The mean prevalence of ICU-acquired infections was 21%, but varied widely from 10% in Switzerland to 32% in Italy \[[@CR3]\]. EPIC II was conducted 15 years later, on May 8, 2007 \[[@CR2]\]. Data were collected from 13796 adult (\>18 years) patients from 1265 ICUs in 75 countries and showed that 51% of patients had at least one infection.

Antimicrobial resistance is an increasing concern in ICUs worldwide. Rates of resistance vary considerably across different countries and regions; for example, ICUs in southern Europe generally have higher rates of resistance than countries in northern Europe and Scandinavia \[[@CR4]\]. Several studies have reported that infection with an antibiotic resistant strain of an organism is associated with greater mortality and costs and longer ICU lengths of stay than infection with the non-resistant strain \[[@CR5]--[@CR9]\]. An important question is whether being admitted to an ICU with high levels of antimicrobial resistance is associated with a worse outcome than being admitted to an ICU with low rates of resistance, but there are few data available on this topic. In the present study, therefore, we used data from the large EPIC II study \[[@CR2]\] to compare the characteristics of infections, antibiotic treatments and patient outcomes in patients admitted to ICUs in countries considered as having high levels of antibiotic resistance, as recorded in the Antimicrobial Resistance Surveillance System (EARSS) 2007 Annual Report, and those admitted to ICUs in countries considered as having low levels of antibiotic resistance. We hypothesized that there would be a difference in outcomes in patients admitted to ICUs in countries with high levels of antimicrobial resistance compared to those admitted to ICUs in countries with low levels of resistance.

Methods {#Sec2}
=======

The worldwide EPIC II 1-day point-prevalence study of infection and demographics of critically ill patients was performed on 8 May 2007 \[[@CR2]\]. Data were collected for 13,796 adult patients in 1265 participating ICUs from 75 countries on the study day. Infection was defined according to the criteria of the International Sepsis Forum \[[@CR10]\]. Microbiological analyses were performed locally. Participating ICUs were asked to provide patient follow-up until hospital discharge or for 60 days.

For the purposes of this analysis, we selected two groups of countries based on the country rate of methicillin-resistant *Staphylococcus aureus* (MRSA) reported in the European Antimicrobial Resistance Surveillance System (EARSS) 2007 Annual Report \[[@CR11]\]: countries with MRSA rates of ≥ 25% in the 2007 report (Greece, Israel, Italy, Malta, Portugal, Spain, and Turkey) and countries with MRSA rates of \< 5% (Denmark, Finland, Netherlands, Norway, and Sweden) (see Appendix for list of participating centres in these countries). Severity scores, source of infection, pathogens, antibiotic resistance, antibiotic therapy (prophylactic and therapeutic, as defined by the attending physician at each centre), co-morbidities, lengths of stay and outcomes were compared in patients in the two groups of countries.

The EPIC II study was approved by the ethics committee of Erasme Hospital, Belgium, the coordinating center. Local ethical committee approval at each participating center (see Appendix for list of participating centers) was expedited or waived because of the observational nature of the study.

Statistical analyses {#Sec3}
--------------------

Statistical analyses were performed using IBM SPSS Statistics 20 for Windows (IBM, Armonk, NY, USA). The Kolmogorov-Smirnov test was used, and histograms and Q-Q plots were examined to verify if there were significant deviations from the normality assumption of continuous variables. Difference testing between groups was performed using Mann-Whitney test, *χ*^2^ test, or Fisher's exact test as appropriate. Logistic regression analysis was used to determine the mortality risk associated with admission to an ICU in a country with high levels of antimicrobial resistance or one with low levels of antimicrobial resistance. To remove any bias of confounding variables for the association between the areas of ICU admission and mortality, a propensity score was estimated for each of the ICU areas, with the following variables considered as factors: type of admission, source of admission, comorbidities, age, sex, mechanical ventilation, haemofiltration or haemodialysis, infection, SAPS II score and type of microorganism. After checking that balance on all covariates that were used in the propensity model had been achieved, odds ratios with mortality as the dependent variable were estimated by logistic regression using two strategies: by matching and by introducing the propensity score in the model \[[@CR12], [@CR13]\]. Reported odds ratios were adjusted for propensity score, hospital and organizational related factors, including type of ICU (closed vs. open, community vs. university, surgical vs. medical), number of ICU beds, number of nurses, number of physiotherapists, presence of 24-h ICU physician coverage, length of ICU stay prior to study day, percentage of gross domestic product spent on health care generated using the World Health Organization Statistical Information System (based on data from 2006 \[[@CR14]\]) and geographical region. Data are presented as median \[interquartile range (IQR)\] or number (%), as appropriate. All tests were two-tailed, and a P \< 0.05 was considered statistically significant.

Results {#Sec4}
=======

In the EPIC II database, there were 2204 patients included from ICUs in countries with high levels of antimicrobial resistance (HighABR) according to the EARSS 2007 Annual Report \[[@CR11]\] and 558 from ICUs in countries with low levels of antimicrobial resistance (LowABR) Table [1](#Tab1){ref-type="table"}). The median SAPS II score was significantly higher in HighABR than in LowABR ICU patients (34 \[26-44\] vs 31 \[25-39\] P \< 0.001) and chronic renal failure and chronic obstructive pulmonary disease (COPD) were significantly more common (Table [1](#Tab1){ref-type="table"}). Patients from HighABR ICUs were more often admitted from the emergency room and less often from the operating/recovery room than were patients from LowABR ICUs. Patients from HighABR ICUs had longer ICU and hospital lengths of stay than patients from LowABR ICUs; the number of days in the ICU prior to the study day was also longer in patients admitted to HighABR ICUs (Table [1](#Tab1){ref-type="table"}).Table 1**Characteristics of study population and participating units**CharacteristicsLowABR countriesHighABR countriesp-valueOf ICUsN = 54N = 231Staffed ICU beds, n (%)\<714 (25.9)67 (29.0)0.97-1430 (55.6)122 (52.8)15+10 (18.5)42 (18.2)Nurse:patient, n (%)\>1:119 (35.2)16 (6.9)\<0.0011:1-1:1.4914 (25.9)42 (18.2)1:1.5-1:1.9918 (33.3)78 (33.8)\<1:23 (5.6)95 (41.1)24-hr in-house intensivist48 (88.9)231 (100%)\<0.001**Of patientsN = 558N = 2204**Age, median (25-75 percentile)65 (53-74)65 (51-74)0.574SAPS II score, median (25-75 percentile)31 (25-39)34 (26-44)\<0.001SOFA score, median (25-75 percentile)5 (3-8)5 (3-8)0.806Length of stay in days in ICU prior to study day, median (25-75 percentile)1 (0-6)4 (0-14)\<0.001Infected255 (45.7)1187 (53.9)0.001Type of admission, n (%)*Surgical, elective*203 (36.5)455 (20.7)\<0.001*Surgical, emergency*200 (36.0)952 (43.2)*Medical*114 (20.5)534 (24.3)*Trauma*39 (7.0)261 (11.9)Admission source, n (%)*OR/recovery*205 (37.7)472 (21.5)\< 0.001*ED/ambulance*111 (20.4)680 (31.0)*Hospital ward*160 (29.4)713 (32.5)*Other hospital*61 (11.2)273 (12.4)*Other*7 (1.3)55 (2.5)Main reason for admission, n (%)*Surveillance/monitoring*158 (28.3)336 (15.2)\< 0.001*Neurological*56 (10.0)350 (15.9)*Respiratory*119 (21.3)527 (23.9)*Cardiovascular*119 (21.3)579 (26.3)*Renal*5 (0.9)33 (1.5)*Digestive/liver*53 (9.5)154 (7.0)*Trauma*36 (6.5)198 (9.0)*Other*12 (2.2)27 (1.2)Co-morbidities, n (%)*COPD*77 (13.8)457 (20.7)\<0.001*Haematological cancer*11 (2.0)49 (2.2)0.715*Cancer*82 (14.7)341 (15.5)0.649*IDDM*42 (7.5)221 (10.0)0.072*Heart Failure (NYHA III-IV)*59 (10.6)231 (10.5)0.949*CRF*14 (2.5)165 (7.5)\<0.001*HIV*2 (0.4)15 (0.7)0.385*Cirrhosis*14 (2.5)65 (2.9)0.577*Immunosuppression*24 (4.3)95 (4.3)0.992Number of co-morbidities, n (%)*None*282 (50.5)1011 (45.9)0.029*1*195 (34.9)746 (33.8)*2*61 (10.9)313 (14.2)*3*16 (2.9)103 (4.7)*\>3*4 (0.7)31 (1.4)Treatments, n (%)*Mechanical ventilation*359 (64.7)1388 (63.1)0.502*Haemofiltration or haemodialysis*47 (8.5)171 (7.8)0.591Length of stay, median (25-75 percentile)ICU5 (1-19)12 (3-31)\< 0.001Hospital16 (7-37)24 (10-54)\<0.001MortalityICU83 (15.4)408 (20.0)0.016Hospital116 (21.5)551 (27.0)0.01OR, operating room; ED, emergency department; COPD, chronic obstructive pulmonary disease; IDDM, insulin-dependent diabetes mellitus; NYHA III-IV, New York Heart Association class III-IV; CRF, chronic renal failure; HIV, human immunodeficiency virus.

Infections and Microbiology {#Sec5}
---------------------------

More patients in the HighABR ICUs than in the LowABR ICUs were infected on the study day (53.9% vs 45.7%, P \< 0.01). The respiratory system was the most common site of infection in all patients (Additional file [1](#MOESM1){ref-type="media"}). The sites of infection were similar in the two groups except for abdominal infections, which were more common in patients admitted to LowABR ICUs (24.3% vs 18.4%, P = 0.03), and bloodstream infections, which were more common in patients admitted to HighABR ICUs (19.6% vs 16.1%, P = 0.03). Culture specimens were positive in 852 (71.8%) of the patients from HighABR ICUs and in 196 (76.9%) of the patients from LowABR ICUs (P = NS). As expected, MRSA was more common in patients in the HighABR ICUs than those in the LowABR ICUs (69/137 \[50%\] vs 2/32 \[6%\], P \< 0.001) (Table [2](#Tab2){ref-type="table"}). Infections caused by *Pseudomonas aeruginosa* or *Actinetobacter* were significantly more prevalent among HighABR ICU patients (Table [2](#Tab2){ref-type="table"}), whereas methicillin-sensitive *S. aureus* (MSSA), enterococci and anaerobes were more common in LowABR ICU patients.Table 2**Microorganisms isolated from the 1048 culture-positive infected patients**LowABR countries (n = 196)HighABR countries (n = 852)P-valuePathogen, n (%)*S. aureus*32 (16.3)137 (16.1)0.993 MRSA2 (1.0)69 (8.1)\<0.001 MSSA30 (15.3)70 (8.2)0.002*S. epidermidis*18 (9.2)117 (13.7)0.087*S. pneumoniae*14 (7.1)39 (4.6)0.139*Enterococci*31 (15.8)92 (10.8)0.049G^+^, others20 (10.2)48 (5.6)0.019*E. coli*36 (18.4)128 (15.0)0.245*Enterobacteriaceae*10 (5.1)52 (6.1)0.592*Klebsiella*21 (10.7)92 (10.8)0.973*P. aeruginosa*27 (13.8)172 (20.2)0.039*Acinetobacter spp*5 (2.6)130 (15.3)\<0.001ESBL-producing4 (2.0)10 (1.2)0.340G^-^, others37 (18.9)136 (16.0)0.322Anaerobes15 (7.7)22 (2.6)\<0.001Bacteria, others3 (1.5)12 (1.4)0.897*Candida*45 (23.0)156 (18.3)0.136*Aspergillus*1 (0.5)8 (0.9)0.557Fungi, others5 (2.6)6 (0.7)0.022Parasites4 (2.0)6 (0.7)0.083Organisms, others12 (6.1)19 (2.2)0.004MRSA, methicillin-resistant S. aureus; MSSA, methicillin-sensitive S. aurues; G^+^, Gram positive; ESBL, extended-spectrum-beta-lactamase; G-, Gram negative.

Antibiotic use {#Sec6}
--------------

### Treatment {#Sec7}

Use of therapeutic antimicrobials was significantly more common overall in HighABR ICU patients than in LowABR ICU patients (54.6% vs 44.4%, P \< 0.001). When considering groups of antimicrobials, carbapenems, aminoglycosides, quinolones and glycopeptides were more commonly used in patients in HighABR ICUs than in LowABR ICUs, whereas cephalosporins were used more frequently as treatment in LowABR ICUs (Table [3](#Tab3){ref-type="table"}). For individual antimicrobials, piperacillin-tazobactam, imipenem/meropenem, amikacin, oxazolidinone and tigecycline were used more frequently in patients in HighABR ICUs; cefazolin, cefuroxime, benzylpenicillin, oxa-/cloxa-/flucloxacillin, erythromycin and metronidazole were used more frequently in patients in LowABR ICUs (Table [3](#Tab3){ref-type="table"}).Table 3**Use of antimicrobials as treatment in infected patients**LowABR ICU patientsHighABR ICU patientsp-value(n = 255)(n = 1187)Antimicrobial, n (%)Cephalosporins (all)84 (32.9)206 (17.4)\<0.001 *Cefazolin*4 (1.6)4 (0.3)0.016 *Cefuroxime*46 (18.0)2 (0.2)\<0.001 *Ceftazidime*8 (3.1)40 (3.4)0.851 *Cefepime/Cefpirome*1 (0.4)24 (2.0)0.070 *Other cephalosporins*26 (10.2)139 (11.7)0.491Penicillins (all)84 (32.9)400 (33.7)0.816 *Benzylpenicillin*16 (6.3)3 (0.3)\<0.001 *Ampicillin*5 (2.0)29 (2.4)0.645 *Amoxycillin + Clavulanic acid*16 (6.3)71 (6.0)0.858 *Piperacillin + Tazobactam*27 (10.6)273 (23.0)\<0.001 *Oxa-/Cloxa-/Flucloxacillin*14 (5.5)16 (1.3)\<0.001 *Other penicillins*8 (3.1)20 (1.7)0.127Other β-lactams (all)44 (17.3)381 (32.1)\<0.001 *Imipenem/meropenem*44 (17.3)365 (30.7)\<0.001 *Aztreonam*0 (0.0)13 (1.1)0.093 *Unspecified beta-lactams*0 (0.0)7 (0.6)0.219Aminoglycosides (all)17 (6.7)202 (17.0)\<0.001 *Amikacin*0 (0.0)114 (9.6)\<0.001 *Tobramycin*11 (4.3)26 (2.2)0.052 *Other aminoglycosides*6 (2.4)66 (5.6)\<0.001Quinolones (all)38 (14.9)242 (20.4)0.045 *Ciprofloxacin*31 (12.2)128 (10.8)0.525 *Other quinolones*7 (2.7)114 (9.7)\<0.001Glycopeptides (all)30 (11.8)272 (22.9)\<0.001 *Vancomycin*30 (11.8)193 (16.3)0.072 *Other glycopeptides*0 (0.0)81 (6.8)\<0.001Macrolides (all)13 (5.1)48 (4.0)0.448 *Erythromycin*6 (2.4)4 (0.3)\<0.001 *Other macrolides*7 (2.7)44 (3.7)0.451Other antibiotics (all)55 (21.6)321 (27.0)0.071 *Metronidazole*36 (14.1)71 (6.0)\<0.001 *Cotrimoxazole*5 (2.0)30 (2.5)0.594 *Oxazolidinone*0 (0.0)128 (10.8)\<0.001 *Tigecycline*0 (0.0)21 (1.8)0.032 *Unspecified*19 (7.5)130 (11.0)0.096Antifungals (all)52 (20.4)209 (17.6)0.295 *Fluconazole*31 (12.2)110 (9.3)0.159 *Amphotericin B*4 (1.6)18 (1.5)0.951 *Amphotericin lipid complex*3 (1.2)21 (1.8)0.502 *Caspofungin*12 (4.7)40 (3.4)0.299 *Voriconazole*1 (0.4)31 (2.6)0.029 *Other antifungals*1 (0.4)2 (0.2)0.477Antivirals (all)3 (1.2)22 (1.9)0.452

### Prophylaxis {#Sec8}

Use of prophylactic antimicrobials was significantly less common in HighABR ICU patients than in LowABR ICU patients (22.2% vs 32.8%, P \< 0.001). Among the agents most commonly used were aminoglycosides (tobramycin), antifungals (amphotericin B) and cephalosporins (Additional file [2](#MOESM2){ref-type="media"}).

Mortality {#Sec9}
---------

Crude ICU (20.0% and 15.4%) and hospital (27.0% vs 21.5%) mortality rates were higher in patients admitted to HighABR than in those admitted to LowABR ICUs (both P \< 0.05); however, these differences were not present after adjustment in multivariable analysis or the matched pair analysis (Table [4](#Tab4){ref-type="table"}). For subgroups of infected or non-infected patients there were no significant differences in crude or adjusted mortality rates between HighABR and LowABR ICUs.Table 4**Crude and adjusted odds ratios\* (95% CI) for ICU and hospital mortality in the whole cohort and in infected patients**OR (95% CI)P-valuem-OR (95% CI)P-valuea-OR (95% CI)P-valueICU mortality (all)1.37 (1.06-1.78)0.0161.14 (0.76-1.73)0.5261.07 (0.78-1.48)0.661Hospital mortality (all)1.35 (1.07-1.69)0.011.07 (0.74-1.55)0.7071.12 (0.84-1.48)0.445ICU mortality (infected)1.23 (0.88-1.72)0.2221.23 (0.73-2.09)0.4380.99 (0.66-1.49)0.95Hospital mortality (infected)1.21 (0.89-1.63)0.2181.02 (0.63-1.65)0.9331.1 (0.77-1.58)0.606ICU mortality (not infected)1.38 (0.91-2.09)0.1311.01 (0.5-2.02)0.9841.32 (0.78-2.22)0.304Hospital mortality (not infected)1.33 (0.93-1.92)0.1211.16 (0.64-2.11)0.6291.19 (0.75-1.9)0.461OR: Odds ratio; m-OR: Odds ratio from matched-pairs. a-OR: adjusted odds ratio. \*With admission to HighABR ICU as the reference category. The list of confounders included in the multivariable analysis is reported in the text.

Patients with infections due to *Pseudomonas aeruginosa* had crude ICU and hospital mortality rates of 32.4% and 42.7%, respectively. Corresponding percentages for patients with *Acinetobacter* infections were 31.7 and 37.3, respectively, and for MRSA 32.3 and 43.1, respectively. Because of the relatively small sample sizes, we were unable to compare outcomes for the different pathogens in the two groups.

Discussion {#Sec10}
==========

The main message of this study is that hospitalization in an ICU in a country with high levels of antimicrobial resistance is not an independent risk factor for worse outcome. We chose to select countries with likely high and low antimicrobial resistance using reported MRSA rates, although acknowledge that general resistance rates may have been different; nevertheless, most countries with high MRSA rates do seem to have high resistance levels among other organisms \[[@CR11]\]. Several studies have shown increased mortality rates in patients with MRSA infections compared to those with MSSA infections \[[@CR15], [@CR16]\]. In an earlier analysis of the EPIC II database, MRSA infection was associated with an increased risk of death compared to MSSA infection (OR 1.46 \[95% CI 1.03-2.06\], P = 0.03) \[[@CR17]\]. Using data from the European Antimicrobial Resistance Surveillance System and the Burden of Resistance and Disease in European Nations project, De Kraker et al. \[[@CR15]\] reported that 27,711 episodes of MRSA blood stream infections (BSIs) were associated with 5,503 excess deaths. The same authors compared two prospective cohorts of patients from 13 ICUs in 13 European countries, one with MRSA and one with MSSA BSIs, each matched with control patients without the respective BSI \[[@CR16]\]. MRSA and MSSA patients had higher 30-day and hospital mortality than the control patients, and MRSA patients had greater 30-day mortality (OR 1.8, P = 0.04) than MSSA patients. Other studies have reported similar mortality rates in MRSA and MSSA patients, but longer lengths of stays and higher associated costs \[[@CR6], [@CR7], [@CR18]\].

Infections due to difficult to treat pathogens, i.e., *P. aeruginosa*, *Acinetobacter spp* and MRSA, were in general associated with higher crude ICU and hospital mortality rates in our study than other infections and were significantly more prevalent in HighABR ICUs; however, because of small sample sizes, comparisons between groups were not possible. We know from other ICU studies that these pathogens are associated with increased attributable mortality if empirical treatment is not appropriate \[[@CR19]--[@CR21]\]. Unfortunately, we are unable to determine whether or not treatment was appropriate in our study, although we did show that broadspectrum antibiotics, such as carbapenems, piperacillin-tazobactam, amikacin, tigecycline, oxazolidinone and vancomycin, were more commonly used for treatment in the HighABR ICUs. Similarly, we did not record antibiograms for the different species and have no data on rates of resistance, except for *S. aureus* and ESBL-producing Gram-negative bacteria. Infections caused by enterococci and anaerobes were more common in LowABR ICU patients which may explain the more frequent abdominal infections and use of metronidazole in these ICUs.

Conclusions {#Sec11}
===========

Infections were more prevalent among patients admitted to ICUs in HighABR countries than in LowABR countries. Antibiotic therapy differed markedly, with broader spectrum antimicrobials being used more frequently in HighABR countries. ICU patients in HighABR countries were sicker and had longer ICU and hospital stays and higher crude ICU and hospital mortality rates, which could have a marked economical impact; however, after multivariate adjustment there were no differences in ICU or hospital mortality rates between the two groups of patients.

Appendix: List of participating centres for this EPIC II substudy by country, alphabetically {#Sec12}
============================================================================================
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